Close menu




June 18th, 2021 | 15:10 CEST

MorphoSys, Biogen, Sierra Growth - What is next?

  • Investments
Photo credits: pixabay.com

Pharmaceutical stocks are a bit like that: Giants like Johnson & Johnson or Novartis have an extensive product portfolio and can cushion failures of individual products quite well. It is often a matter of life and death for smaller, specialized companies with every development. Just yesterday, this could be observed in the CureVac share after its Corona vaccine candidate only achieved an efficacy of 47% in the clinical 2b/3 phase. Within a very short time, it disintegrated the stock price. Meanwhile, biotech pioneer Biogen surprised with an unjustified share price rally, which, however, could come to an abrupt end after a new setback. The situation is different for MorphoSys. Its planned acquisition of Constellation Pharmaceuticals initially weighed heavily on the share price, but it holds exciting potential. And the Canadian mining Company Sierra Growth is operating in a completely different environment; however, it has a top opportunity to offer in the current inflationary environment and should not go unmentioned.

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: DE0006632003 , US09062X1037 , CA8263191055

Table of contents:


    MorphoSys - Slow but steady price recovery

    One of the "stock market winners" of the last few days is the biopharmaceutical Company MorphoSys. The Germans, dedicated to discovering, developing, and marketing innovative antibody therapies against cancer and autoimmune diseases, had already announced on June 2 the planned acquisition of Cambridge, US-based Constellation Pharmaceuticals. The announcement initially led to a drop in the share price of almost 15% due to the immense purchase price. However, the stock has since slowly recovered. Now the cash offer to acquire the remaining shares has been made: the Munich-based Company is prepared to pay the shareholders of Constellation Pharmaceuticals USD 34 per share, or a total of around USD 1.7 billion. The offer is valid until July 14. The offer is subject to additional conditions, such as the tender of at least a majority of the shares, the observance of a waiting period, and other customary restrictions.

    MorphoSys expects to complete the merger in the third quarter. With the acquisition of Constellation, the Martinsried-based Company hopes to fill its product pipeline with promising candidates. However, the Company is also entering new territory with the field of epigenetics, which has not previously been part of its research approach. Constellation's most advanced product to date is Pelabresib, an active ingredient against myelofibrosis, a rare form of bone marrow cancer. The experts at JPMorgan believe the drug has expected peak annual sales of USD 1.7 billion. However, the drug will not complete Phase 3 clinical trials until late 2022. While the experts at JPMorgan, who see only a 50% probability of success for Pelabresib and criticize delays in the launch of the blood cancer drug Monjuvi in the US, have downgraded the MorphoSys share to neutral. Their colleagues at Berenberg Bank take a much more positive view of the acquisition with a price target of EUR 140. The stock is a clear buy for the Hanseatic bankers. Courageous investors can take advantage of the current share price weakness of MorphoSys.

    Sierra Growth - Exciting Micro Cap

    There are different types of investors: some are long-term oriented and primarily overweight stocks that currently appear undervalued. Others focus mainly on blue chips and dividend stocks. And still others like the thrill and like to invest in companies that promise high profits in a short time. If you are currently looking for a stock from the last group, you should look at the junior exploration Company Sierra Growth Inc. Based in the Canadian province of British Columbia, the Company specializes in the exploration of gold, silver, copper and molybdenum projects in their absolute early stages. The Company has focused on two regions: the US state of Nevada and the Andean country of Peru. In Peru, the Company, until recently, held exploration rights to two properties near the capital Lima, Silviera and Española.

    However, the rights for Silviera were sold to the Peruvian CIEMSA group for USD 1 million last October. Given the looming election victory of the Marxist-Leninist presidential candidate Pedro Castillo, who has already announced a massive tax increase for foreign mining companies, this was undoubtedly a good move. At any rate, the focus is currently on the Nevada region. Here, the Company is currently exploring three projects: Glitra/Sat, Mildred/B&C Springs and Betty East, all of which are located on the Walker Lane trend, which is historically known to be high-grade. The collection of 1,805 soil geochemical samples at 50m to 100m intervals was completed in late May. Results are expected by the end of June/early July at the latest. Therefore, this is the ideal time for fortune seekers to get in on the action. Should the soil samples imply significant mineral deposits, this can positively influence the Company's share price within a very short time. The stock is also traded in Frankfurt and is currently valued at around CAD 8 million.

    Biogen - Protests and failures on the Alzheimer's front could end share price rally

    Since the beginning of June, the Biogen share has shown a brilliant price rally; the price increase amounted to almost 60%. What happened? Despite a clear vote last November by an advisory panel to the US Food and Drug Administration (FDA) that Biogen's new Alzheimer's therapy, called "Aduhelm," was not proven effective, by a vote of 10 to 0 with one abstention, the FDA now granted approval. Although three advisory panel members subsequently resigned in protest against the decision, this first approval of a therapy in more than 18 years nevertheless boosted the market's share price fantasies. It is quite possible that this is now over.

    On Wednesday, the Company had to concede that a second drug candidate against Alzheimer's, Gosuranemab, based on an anti-tau antibody, had not shown the required statistical efficacy in Phase 2 clinical trials. The Company announced that it would discontinue further research on the drug. Although Biogen currently has another drug candidate against Alzheimer's disease in a Phase 3 trial, there is now a distinct possibility that investors will first try to take profits from the share price rally. Although analysts' median price target is still just above the current price, the majority of them recommend "hold."


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?

    Read

    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read